Clinical Trial Update: A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis From France Who Completed WA19977 Core Study [Phase 3]

View source ↗

Summary

This document reports a long-term extension study of tocilizumab (RoActemra/Actemra) in pediatric patients with Juvenile Idiopathic Arthritis who completed the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Juvenile Idiopathic Arthritis

Drugs mentioned

• RoActemra/Actemra (tocilizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Juvenile Idiopathic Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2016-11-02